Casting doubt on the traditional approach of cancer biomarker discovery through proteomics

Expert Review of Proteomics
Tadashi Kondo

Abstract

Towards revolutionary biomarkers, a considerable amount of research funds and time have been dedicated to proteomics. Although the discovery of novel biomarkers at the dawn of proteomics was a promising development, only a few identified biomarkers seemed to be beneficial for cancer patients. We may need to approach this issue differently, instead of only extending the conventional approaches that have been used historically. The study of biomarkers is essentially a study of diseases and the biochemistry relating to peptide, protein and post-translational modifications is only a tool. A problem-oriented approach should be needed in biomarker development. Clinician participation in the study of biomarkers will lead to realistic, practical and interesting biomarker candidates, which justify the time and expense involved in validation studies. Although discussion in this article is focused on cancer biomarkers, it can generally be applied to biomarker studies for other diseases.

References

Feb 2, 2002·Nature·Laura J van 't VeerStephen H Friend
Dec 19, 2002·Molecular & Cellular Proteomics : MCP·N Leigh Anderson, Norman G Anderson
Oct 31, 2003·Nature·Lance A LiottaEmanuel Petricoin
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Feb 3, 2005·Nature Reviews. Cancer·David F Ransohoff
Sep 22, 2005·Journal of the National Cancer Institute·Karyn Hede
Nov 1, 2006·BMC Genomics·Annuska M GlasLaura J Van't Veer
Mar 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yoshiyuki SueharaSetsuo Hirohashi
Dec 30, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David F Ransohoff, Margaret L Gourlay
Apr 24, 2012·European Journal of Clinical Investigation·Harald MischakAntonia Vlahou

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Related Papers

Expert Review of Molecular Diagnostics
Thomas P ConradsTimothy D Veenstra
Current Drug Targets. Immune, Endocrine and Metabolic Disorders
Thomas P Conrads, Timothy D Veenstra
Rinsho byori. The Japanese journal of clinical pathology
Tadashi Kondo
Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery
Wuttipong TirakotaiIlhan Celik
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Sergio CiordiaJuan-Pablo Albar
© 2021 Meta ULC. All rights reserved